SWOG Cancer Research Network
Vinblastine (Velban)(SWOG Cancer Research Network)은 Anaplastic Large Cell Lymphoma, ALK-Posi 표적 ADC로, Anaplastic Large Cell Lymphoma, ALK-Positive 영역에서 개발·상용화 중입니다. 작용기전: targeting both microtubule stabilization and proteostasis pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 96% (ClinicalTrials.gov NCT00722865). 차별점: novel pyrazolotriazole pyrimidine derivatives using a one-pot, three-component reaction involving 5-aminotetrazole, aromatic.
Anaplastic Large Cell Lymphoma, ALK-Posi
Anaplastic Large Cell Lymphoma, ALK-Positive
Recruiting
NK cells, DCs) and checkpoint expression (CCL19, BTLA)
Vedotin Plus AVD versus ABVD in Egyptian Patien
novel pyrazolotriazole pyrimidine derivatives using a one-pot, three-component reaction involving 5-aminotetrazole, aromatic
targeting both microtubule stabilization and proteostasis pathway
apoptosis
PD-L1-high
downregulation in OS samples
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
SWOG Cancer Research Network
Vinblastine (Velban)(SWOG Cancer Research Network)은 Anaplastic Large Cell Lymphoma, ALK-Posi 표적 ADC로, Anaplastic Large Cell Lymphoma, ALK-Positive 영역에서 개발·상용화 중입니다. 작용기전: targeting both microtubule stabilization and proteostasis pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 96% (ClinicalTrials.gov NCT00722865). 차별점: novel pyrazolotriazole pyrimidine derivatives using a one-pot, three-component reaction involving 5-aminotetrazole, aromatic.
Anaplastic Large Cell Lymphoma, ALK-Posi
Anaplastic Large Cell Lymphoma, ALK-Positive
Recruiting
NK cells, DCs) and checkpoint expression (CCL19, BTLA)
Vedotin Plus AVD versus ABVD in Egyptian Patien
novel pyrazolotriazole pyrimidine derivatives using a one-pot, three-component reaction involving 5-aminotetrazole, aromatic
targeting both microtubule stabilization and proteostasis pathway
apoptosis
PD-L1-high
downregulation in OS samples
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.